This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star.

medigene-logo-frontMedigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts roughly 70 employees and has a market cap of 150 million euros. Peter Llewellyn-Davies has previously worked as CFO of Wilex AG and been in the board of ImmunoCore (the UK Biotech which raised $330 million in a private round!!)

It was very exciting to meet Peter and interviewing him on Medigene’s dendritic cells vaccines, its TCR program as well as its financial situation.

Check it out:

Bonus – Medigene did a great animation video on how its TCR works. Worth checking out too:

Previous post

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

Next post

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015